Sana Biotechnology Inc (SANA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $605.26M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sana Biotechnology Inc (SANA) Stock Forecast
Analysts expect Sana Biotechnology (SANA) to earn -$0.49 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 8 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 6 | 66.7% |
| Hold | 1 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.49
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.44
- EPS consensus
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.49 | -$0.60 to -$0.30 | 4 |
| Dec 31, 2027 | -$0.44 | -$0.58 to -$0.22 | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.18 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.18 | -$0.26 to -$0.09 | 12 |
| Mar 31, 2027 | -$0.10 | -$0.10 to -$0.10 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.58.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.49 | -$0.59 | -$0.59 | -$0.59 | -$0.58 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.44 | -$0.56 | -$0.56 | -$0.56 | -$0.52 | N/A |
Frequently Asked Questions About SANA
What is the SANA stock forecast?
Consensus analyst estimates put Sana Biotechnology's EPS at -$0.49 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.
How do analysts rate SANA stock?
Of 9 analysts covering Sana Biotechnology, 2 rate it Strong Buy, 6 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SANA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.49, with estimates from -$0.60 to -$0.30 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.44, with estimates from -$0.58 to -$0.22 from 4 analysts.
How many analysts cover SANA?
9 analysts rate Sana Biotechnology stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SANA pages: Overview, Earnings, Forecast, Financials, Competitors